HCQ drug was chosen in the present study to test whether it was involved with ACE2; this drug was the drug most administered in patients at the beginning of the COVID‐19 pandemic; unfortunately, without any conclusive beneficial effect, it is not included as a cocktail drug for COVID‐19 treatment. The gene discussed is ACE2; the disease is COVID-19.